Teplizumab Slows Beta Cell Decline in Newly Diagnosed Teens with Type 1 Diabetes

The PROTECT trial enrolled 328 children and adolescents aged 8–17 who had recently been diagnosed with stage 3 type 1 diabetes. Participants received either two 12-day courses of teplizumab or a placebo, given intravenously.

Researchers tracked how well each person's pancreas could still produce insulin by measuring C-peptide levels—a marker of beta cell function. They also monitored insulin dosing, blood sugar control, and time spent within target glucose ranges.

Among the 275 participants who completed the trial according to protocol (180 receiving teplizumab, 95 receiving placebo), those on teplizumab showed significantly better preservation of beta cell function at 78 weeks. The difference in C-peptide levels between the two groups was measurable and statistically significant.

This preservation mattered in practical terms: young people on teplizumab required less insulin overall and spent more time with their blood sugar in range compared to the placebo group. These are meaningful improvements in daily diabetes management.

Researchers examined whether teplizumab worked better or worse depending on certain genetic markers (HLA-DR3 and HLA-DR4) or the pattern of autoantibodies present at diagnosis. The treatment preserved C-peptide levels more effectively than placebo in all subgroups tested.

This suggests the drug's benefit is not limited to a single genetic profile, which is important for understanding which young people might benefit from treatment.

Teplizumab delays the decline of beta cell function in early-stage type 1 diabetes. It does not stop the immune attack entirely or restore lost function. Over time, beta cells continue to decline in both teplizumab and placebo groups, but the teplizumab group declines more slowly.

For young people and families, this preserved beta cell function can translate to lower insulin doses, better blood sugar stability, and potentially fewer extreme highs and lows. However, type 1 diabetes still requires insulin and careful management; teplizumab is an additional tool, not a replacement for standard care.

Source: Diabetologia. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.